Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | RXRG | P48443 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201074 | 0.87 | RXRA (0.70) | RXRARXRBRXRGMCL1PTGER1 | |
| SCHEMBL13740358 | 0.83 | RXRA (0.75) | RXRARXRBRXRGMCL1PTGER1 | |
| SCHEMBL26013299 | 0.81 | MAPT (0.63) | RXRARXRBRXRGMCL1PTGER1 | |
| SCHEMBL5096390 | 0.81 | RXRA (0.67) | RXRARXRBRXRGMCL1PTGER1 | |
| SCHEMBL5109238 | 0.80 | PTGER1 (0.66) | RXRARXRBRXRGMCL1PTGER1 | |
| SCHEMBL7673601 | 0.80 | TDP1 (0.45) | RXRARXRBRXRGMAPK1TDP1 | |
| SCHEMBL13738963 | 0.80 | RXRA (0.71) | RXRARXRBRXRGMCL1PTGER1 | |
| SCHEMBL1423699 | 0.79 | CYP11B1 (0.60) | RXRARXRBRXRGMCL1PTGER1 | |
| SCHEMBL3786776 | 0.79 | MAPT (0.58) | RXRARXRBRXRGMCL1PTGER1 | |
| SCHEMBL10093045 | 0.79 | SYK (0.63) | RXRARXRBRXRGMCL1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-6166072-A | Amino acid derivatives | ALLELIX NEUROSCIENCE, INC. (CA) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | RXRA 2906/4885RXRB 3075/4885RXRG 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.